Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

breast cancer

  • You have access
    Radioguided Surgery (Letter to the Editor)
    Giuliano Mariani, Renato A. Valdés Olmos, Sergi Vidal-Sicart and Harry William Strauss
    Journal of Nuclear Medicine January 15, 2021, jnumed.120.261888; DOI: https://doi.org/10.2967/jnumed.120.261888
  • Open Access
    Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
    Matthias D'Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte and Marleen Keyaerts
    Journal of Nuclear Medicine December 4, 2020, jnumed.120.255679; DOI: https://doi.org/10.2967/jnumed.120.255679
  • You have access
    Sentinel Lymph Node Biopsy in breast cancer with 99mTc-Tilmanocept: A novel tracer in the real life. A multicenter study
    Sergi Vidal-Sicart, María Eugenia Rioja, Andrea Prieto, Elena Goñi, Isabel Gómez, María Dolores Albala, Luis Lumbreras, Luisa Fernanda León, José Ramón Gómez and Francisco Campos
    Journal of Nuclear Medicine October 9, 2020, jnumed.120.252064; DOI: https://doi.org/10.2967/jnumed.120.252064
  • You have access
    Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
    Caroline Rousseau, David M. Goldenberg, Mathilde Colombié, Jean-Charles Sébille, Philippe Meingan, Ludovic Ferrer, Pierre Baumgartner, Evelyne Cerato, Damien Masson, Mario Campone, Aurore Rauscher, Vincent Fleury, Catherine Labbe, Alain Faivre Chauvet, Jean-Sebastien Fresnel, Claire Toquet, Jacques Barbet, Robert M. Sharkey, Loic Campion and Françoise Kraeber-Bodéré
    Journal of Nuclear Medicine August 1, 2020, 61 (8) 1205-1211; DOI: https://doi.org/10.2967/jnumed.119.236000
  • You have access
    Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer
    Gary A. Ulaner, Komal Jhaveri, Sarat Chardarlapaty, Vaios Hatzoglou, Christopher Riedl, Jason S. Lewis and Andrey Mauguen
    Journal of Nuclear Medicine July 17, 2020, jnumed.120.247882; DOI: https://doi.org/10.2967/jnumed.120.247882
  • You have access
    Initial Studies with 11C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer
    Anat Biegon, Kenneth R. Shroyer, Dinko Franceschi, Jasbeer Dhawan, Mouna Tahmi, Deborah Pareto, Patrick Bonilla, Krystal Airola and Jules Cohen
    Journal of Nuclear Medicine June 1, 2020, 61 (6) 807-813; DOI: https://doi.org/10.2967/jnumed.119.231589
  • You have access
    Breast Cancer 18F-ISO-1 Uptake as a Marker of Proliferation Status
    Elizabeth S. McDonald, Robert K. Doot, Anthony J. Young, Erin K. Schubert, Julia Tchou, Daniel A. Pryma, Michael D. Farwell, Anupma Nayak, Amy Ziober, Michael D. Feldman, Angela DeMichele, Amy S. Clark, Payal D. Shah, Hsiaoju Lee, Sean D. Carlin, Robert H. Mach and David A. Mankoff
    Journal of Nuclear Medicine May 1, 2020, 61 (5) 665-670; DOI: https://doi.org/10.2967/jnumed.119.232363
  • You have access
    Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer
    Nicholas Ramos, Jairo Baquero-Buitrago, Zakia Ben Youss Gironda, Youssef Zaim Wadghiri, Thomas Reiner, Fernando E. Boada and Giuseppe Carlucci
    Journal of Nuclear Medicine March 1, 2020, 61 (3) 437-442; DOI: https://doi.org/10.2967/jnumed.119.232603
  • You have access
    Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer
    Manoj Kumar, Kelley Salem, Amye J. Tevaarwerk, Roberta M. Strigel and Amy M. Fowler
    Journal of Nuclear Medicine February 1, 2020, 61 (2) 172-176; DOI: https://doi.org/10.2967/jnumed.119.228858
  • You have access
    Multiparametric 18F-FDG PET/MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer?
    Doris Leithner, Thomas H. Helbich, Blanca Bernard-Davila, Maria Adele Marino, Daly Avendano, Danny F. Martinez, Maxine S. Jochelson, Panagiotis Kapetas, Pascal A.T. Baltzer, Alexander Haug, Marcus Hacker, Yasemin Tanyildizi, Elizabeth A. Morris and Katja Pinker
    Journal of Nuclear Medicine January 1, 2020, 61 (1) 20-25; DOI: https://doi.org/10.2967/jnumed.119.230003

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire